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Ledipasvir-Sofosbuvir for treating Chronic Hepatitis C: A NICE Single Technology Appraisal - An 
Evidence Review Group Perspective 
 
Thokala P, Simpson E, Tappenden P, Stevens J, Dickinson K, Ryder S, Harrison P. 
 
 
Abstract 
The National Institute for Health and Care Excellence (NICE) invited Gilead, the company manufacturing 
ledipasvir-sofosbuvir (LDV/SOF), to submit evidence for the clinical effectiveness and cost-effectiveness of 
LDV/SOF for treating Chronic Hepatitis C. The School of Health and Related Research (ScHARR) Technology 
Assessment Group was commissioned as the Evidence Review Group (ERG). This paper describes the 
company¶V submission (CS), the ERG review and the subsequent decision of the NICE Appraisal Committee 
(AC). The ERG produced a critical review of the clinical effectiveness and cost-effectiveness evidence of 
LDV/SOF based upon the CS.   
 
The clinical effectiveness data for LDV/SOF were taken from ten trials, comprised of three Phase III trials and 
seven Phase II trials. Trials compared different durations of LDV/SOF, with and without ribavirin (RBV). There 
were no head-to-head trials comparing LDV/SOF with any comparator listed in the NICE scope. Data from the 
trials were mostly from populations with genotype 1 (GT1) disease, although some limited data were available 
for populations with genotypes 3 and 4. For GT1 treatment-naïve patients, sustained viral response for 12 weeks 
(SVR12) rates for LDV/SOF ranged from 93.1% to 99.4% for subgroups of patients with non-cirrhotic disease, 
whilst SVR rates of 94.1% to 100% were reported for subgroups of patients with compensated cirrhosis. For 
GT1 treatment-experienced patients, SVR12 rates ranging from 95.4% to 100% were reported for subgroups of 
non-cirrhotic patients and SVR rates ranging from 81.8% to 100% were reported within subgroups of patients 
with compensated cirrhosis.  
Comparator data were not searched systematically as part of the submission, but were based on the coPSDQ\¶V
previous NICE submission of sofosbuvir, with additional targeted searches.  
7KH (5*¶V FULWLFDO DSSUDLVDO RI WKH FRPSDQ\¶V HFRQRPLF HYDOXDWLRQ KLJKOLJKWHG D QXPEHU RI FRQFHUQV The 
ERG¶V base case analyses suggested that the incremental cost effectiveness ratios (ICERs) for LDV/SOF 
(+RBV) are dependent on a) treatment durations, b) whether patients have been previously treated and c) 
whether patients have liver cirrhosis or not.  
 
The AC concluded that it was appropriate to use the approach taken in the (5*¶VH[SORUDWRU\DQDO\VHVLQOLQH
with the marketing authorisation, which considered people with and without cirrhosis separately, and estimated 
the cost-effectiveness for each recommended treatment duration of LDV/SOF.  
  
Key points for decision makers 
 
x The clinical effectiveness data for LDV/SOF were taken from ten trials, comprised of three Phase III 
trials and seven Phase II trials. Trials compared different durations of ledipasvir-sofosbuvir 
(LDV/SOF), with and without ribavirin (RBV). Data from the trials were mostly from populations with 
genotype 1 (GT1) disease, although some limited data were available for populations with genotypes 3 
and 4. 
x The analysis suggested that the ICERs for LDV/SOF (+RBV) are dependent on duration of treatment, 
whether the patients are previously treated and cirrhosis status. In particular, the treatment duration 
chosen (within the EMA recommended treatment durations) for the corresponding patient group has a 
marked impact on the cost-effectiveness results. 
  
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for 
providing national guidance on promoting good health and preventing and treating ill health in priority areas 
with significant impact. Health technologies must be shown to be clinically effective and to represent a cost-
effective use of resources to be recommended for use within the National Health Service (NHS) in England. The 
NICE Single Technology Appraisal (STA) process covers new technologies, within single indications, usually 
soon after the UK marketing authorisation [1]. Within the STA process, the company provides a written 
submission, alongside a health economic model which summarises their estimates of the cost-effectiveness of 
the technology. This submission is reviewed by an external academic organisation, the Evidence Review Group 
(ERG), which consults with clinical specialists to produce an ERG report. After consideration of the company¶V 
submission (CS), the ERG report and testimony from experts and other stakeholders, the NICE Appraisal 
Committee (AC) formulates their preliminary guidance, on which stakeholders are invited to comment. 
Following this, a subsequent Appraisal Consultation Document (ACD) may be produced or a Final Appraisal 
Determination (FAD) issued, which is open to appeal.  
 
This paper provides a summary of the CS [2], the ERG report [3] and of the subsequent development of the 
NICE guidance for the use of ledipasvir-sofosbuvir (LDV/SOF) for treating chronic hepatitis C in England. Full 
details of all relevant appraisal documents, including the NICE scope, ERG report, CS, submissions from other 
consultees, FAD and comments from consultees and commentators can be found on the NICE website [4]. 
 
2. The clinical condition and current treatment 
The CS [2] defined chronic hepatitis C as having persistent, detectable serum Hepatitis C Virus (HCV) 
ribonucleic acid (RNA) for a period greater than 6 months and stated that untreated patients with chronic 
hepatitis C are at progressive risk of liver fibrosis, compensated cirrhosis, decompensated cirrhosis, 
hepatocellular carcinoma and death, as well as extrahepatic diseases. The CS [2] also stated that chronic 
hepatitis C is a common cause of liver cirrhosis and a common indication for liver transplantation in Europe.  
There are six major HCV RNA genotypes (GT1±6). Sentinel surveillance data in England from 2009 to 2013 
show GT1 (45%) and GT3 (45%) predominating, with other genotypes, including GT4, comprising just 10% of 
infections. LDV/SOF holds a European marketing authorisation for patients with genotype 1 (GT1) and 
genotype 4 (GT4) chronic hepatitis C and LDV/SOF with the addition of ribavarin (RBV) is licensed for GT3 
patients with cirrhosis and/or prior treatment failure [5].  
At the time of submission, the CS [2] stated that current relevant treatment options include pegylated interferon 
(PEG-IFN), sofosbuvir [SOF], simeprevir [SMV], telaprevir (TVR), RBV and boceprevir (BOC). Other 
treatment options that have been licensed subsequently (e.g daclatasvir and ombitasvir-paritaprevir-ritonavir 
with or without dasabuvir), were not included as comparators in the CS [2]. 
3. The technology 
LDV is a HCV inhibitor targeting the HCV NS5A protein and SOF is a pan genotypic inhibitor of the HCV 
NS5B RNA-dependent RNA polymerase. SOF is a nucleotide prodrug that undergoes intracellular metabolism 
to form the pharmacologically active uridine analogue triphosphate (GS 461203), which, when incorporated into 
HCV RNA by the NS5B polymerase, acts as a chain terminator. According to the CS [2], GS 461203 (the active 
metabolite of SOF) is neither an inhibitor of human deoxyribonucleic acid (DNA) and RNA polymerases nor an 
inhibitor of mitochondrial RNA polymerase.  
LDV/SOF is administered in tablet form. Each tablet contains 90mg LDV and 400mg SOF. The recommended 
dose is once daily with or without food and the recommended course is either 8 weeks, 12 weeks or 24 weeks 
depending on the SDWLHQW¶Vgenotype, their cirrhosis status and whether they have failed prior treatment [5]. The 
list price for a 28 day pack of LDV/SOF tablets is £12,993.33 [6]. The CS [2] stated that there is no requirement 
for response-guided therapy (RGT) with LDV/SOF and no tests or investigations are required in addition to 
current routine hepatitis tests. 
 
4. The independent ERG report 
 
The ERG report [3] comprised a critical review of the evidence for the clinical effectiveness and cost-
effectiveness of the technology, based upon the CS [2] to NICE. As part of the process, the ERG and NICE had 
the opportunity to obtain clarification on specific points in the CS [2], resulting in the company providing 
additional evidence. The ERG used alternative parameter values and assumptions in the model to produce an 
ERG base case. The evidence presented in the CS [2] DQG WKH(5*¶V UHYLHZRI WKDWHYLGHQFH LV VXPPDULVHG 
here. 
4.1 Clinical evidence  
The clinical effectiveness evidence for LDV/SOF was based on ten trials. These comprised three Phase III trials 
and seven Phase II trials. Trials compared different durations of LDV/SOF, with and without RBV. There were 
no head-to-head trials comparing LDV/SOF with any of the comparators listed in the final NICE scope. The 
Phase III trials, ION-1 [7], ION-2 [8] and ION-3 [9], were designed to compare different durations of LDV/SOF 
with or without RBV, with only historical controls for comparison. 
Data from the trials were mostly from populations with GT1 disease, although limited data were also available 
for populations with genotypes 3 and 4. Treatment-naïve and treatment-experienced patients were represented 
within the trials. All ten trials reported sustained virologic response outcomes at 12-week post-treatment 
(SVR12). The Phase III trials provided data on resistance, health-related quality of life (HRQoL), and adverse 
events (AEs). One of the Phase II trials also contributed AE data. 
For GT1 treatment-naïve patients, SVR12 rates for LDV/SOF ranged from 93.1% to 99.4% for subgroups of 
patients with non-cirrhotic disease, whilst SVR rates of 94.1% to 100% were reported for subgroups of patients 
with compensated cirrhosis. For GT1 treatment-experienced patients, SVR12 rates ranging from 95.4% to 100% 
were reported for subgroups of non-cirrhotic patients and SVR rates ranging from 81.8% to 100% are reported 
within subgroups of patients with compensated cirrhosis. 
The most common AEs for LDV/SOF-treated patients were fatigue, headache, insomnia, and nausea. Across the 
treatment arms of the Phase III trials, 67% to 93% of patients experienced at least one AE. Of these, the majority 
were mild to moderate in severity. 
Comparator data were not searched systematically as part of the CS [2], but were instead based on the 
FRPSDQ\¶VSUHYLRXV1,&(VXEPLVVLRQRIVRIRVEXYLUZLWKDGGLWLRQDOWDUJHWHGVHDUFKHV 
7KH(5*¶Vinterpretation of clinical evidence  
 
The ERG considered that all trials of LDV/SOF relevant to the NICE scope were included in the CS [2]. Despite 
adopting an open-label design, the three Phase III LDV/SOF trials were generally considered to be at a low risk 
of bias. However, they were designed to compare different durations of LDV/SOF, with or without RBV, and 
none contained a placebo arm or a comparator without LDV/SOF. The ERG had concerns about the absence of 
a comparator arm & use of historical controls in the study design. Randomisation was stratified in the Phase III 
trials allowing a pre-specified investigation of treatment effect by subgroup. The Phase II trials had small 
sample sizes but provided data consistent with the Phase III trials. 
 
Comparator data were not searched systematically as part of the submission. Historical controls were selected, 
from single arms of randomised controlled trials (RCTs), or non-RCTs EDVHGRQWKHFRPSDQ\¶VSUHYLRXV1,&(
submission of sofosbuvir, with additional targeted searches. Although reported baseline characteristics appear 
similar between intervention and comparator trials, the possibility that other factors differed across trials cannot 
be ruled out. 
 
The approach to searching the evidence base for comparator terms and AEs was not systematic, especially given 
the use of targeted searches and the absence of a full systematic review. Whilst it is unlikely that there were any 
major omissions in the studies retrieved, there is potential for some evidence to have been missed and the 
overall reporting of the searches was insufficient to allow the ERG to make a fully informed critique of this 
element of the appraisal. 
 
SVR12 data were used as a measure of treatment effectiveness. Historically, sustained virologic response at 24-
weeks post-treatment (SVR24) has been used to measure patient response to therapy. However, research from 
clinical trials has indicated a high concordance between SVR12 and SVR24 [10;11], and SVR12 is now 
considered an appropriate endpoint for regulatory approval [5]. Thus, the ERG considered the use of SVR12 
data to be appropriate.  
 
4.2 Cost-effectiveness evidence  
The CS [2] included a systematic review of published economic evaluations of treatments for hepatitis C. The 
FRPSDQ\¶VUHYLHZZDVVXEVWDQWLDOLQFOXGLQJXQLTXHFLWDWLRQV7KHPDLQERG\RIWKH&6 [2]  summarised the 
economic comparisons made for the intervention and comparators defined in the NICE scope, including a list of 
studies in which the intervention was found to be dominant or cost-effective (acceptability criterion 
unspecified).  
 
The company also submitted a de novo health economic model to evaluate the cost-effectiveness of 
LDV/SOF+/-RBV against relevant comparators for patients with GT1, GT3 and GT4. 7KH FRPSDQ\¶V PRGHO
included a total of twelve health states, including two death states, to represent the progression of liver disease 
and the costs and health benefits associated with curing HCV. All analyses adopted a lifetime horizon. The 
effectiveness of treatment was driven by SVR12 rates which were assumed to determine whether cure is 
achieved, whilst the cost-effectiveness of antiviral treatment was driven by the costs and benefits of the antiviral 
treatment and the avoidance of long-term costs and consequences associated with disease progression. Relative 
treatment benefits were modelled using naïve indirect comparisons between individual trial arms from multiple 
studies.  
 
Health-related quality of life (HRQoL) was captured within the model by assigning different health utilities to 
each health state. In addition, the utilities associated with on treatment health states differ for each treatment 
option; this was intended to reflect the disutility impacts of treatment-specific AEs. The model included costs 
associated with drug treatment, the management of treatment-related AEs, monitoring and health state costs 
(e.g. post-treatment monitoring, liver transplantation and post-transplantation follow-up).  
 
7KHFRPSDQ\¶V base case analysis included separate economic comparisons for seven subgroups of patients: (i) 
GT1 treatment-naïve; (ii) GT4 treatment-naïve; (iii) GT1/4 treatment-experienced; (iv) GT3 treatment-naïve; (v) 
GT3 treatment-naïve with compensated cirrhosis; (vi) GT3 treatment-experienced IFN ineligible; and, (vii) GT3 
treatment-experienced IFN-ineligible with compensated cirrhosis. 7KHFRPSDUDWRUVFRQVLGHUHGLQWKHFRPSDQ\¶V
economic analysis differed according to the characteristics of the population and the licensed indications for 
each drug/combination; these include: (i) PEG-IFN2a+RBV; (ii) SMV+PR; (iii) TVR+PEG-IFN2a+RBV; (iv) 
BOC+PEG-IFN2b+RBV; (v) SOF+ PEG-IFN2a+RBV; (vi) SOF+SMV; (vii) SOF+RBV, and; (viii) no 
treatment. 
 
,Q WKH FRPSDQ\¶V DQDO\VLV RI VXbgroups of patients with GT1 and GT4 disease, the costs and outcomes of 
/'962)DUHEDVHGRQ D³EOHQGHG´DSSURDFK7KLVEOHQGHG approach involves taking a weighted average of 
SVR rates (and costs) of LDV/SOF given over different treatment durations based on FRPSDQ\¶VDVVXPSWLRQV
about the expected proportion of patients who would receive each. 
 
7KHFRPSDQ\¶VPRGHOVXJJHVWed that for all subgroups, LDV/SOF is expected to be the most effective treatment 
option (see Table 1 for WKH FRPSDQ\¶V FRVW-effectiveness results for LDV/SOF compared pairwise with each 
comparator). Within the GT1 treatment-naïve subgroup, the incremental cost-effectiveness ratio (ICER) for 
LDV/SOF versus PEG-IFN2a+RBV (the next most effective non-dominated option) was estimated to be £7,985 
per QALY gained. Within the GT4 treatment-naïve subgroup, the ICER for LDV/SOF versus PEG-IFN2a+RBV 
(the next most effective non-dominated option) was estimated to be £12,715 per QALY gained. Within the 
GT1/4 treatment-experienced subgroup, the ICER for LDV/SOF versus no treatment (the next most effective 
non-dominated option) was estimated to be £13,527 per QALY gained. Within the GT3 treatment-naïve 
subgroup, the ICER for LDV/SOF versus PEG-IFN2a+RBV (the next most effective non-dominated option) 
was estimated to be £26,491 per QALY gained. Within the GT3 treatment-naïve with compensated cirrhosis 
subgroup, the ICER for LDV/SOF+RBV versus SOF+PEG-IFN2a+RBV (the next most effective non-
dominated option) was estimated to be £46,491 per QALY gained. Within the GT3 treatment-experienced IFN-
ineligible subgroup, the ICER for LDV/SOF+RBV versus no treatment was estimated to be £28,048 per QALY 
gained. Within the GT3 treatment-experienced IFN-ineligible cirrhotic subgroup, the ICER for LDV/SOF 
+RBV versus SOF+RBV was estimated to be £6,210 per QALY gained. 
 
Table 1. Summary of the compDQ\¶VFRVW-effectiveness results for ledipasvir±sofosbuvir compared 
pairwise with each comparator (£/QALY gained) 
 
Indication Base case Non-cirrhotic Cirrhotic 
Previously untreated genotype 1 HCV 
SOF+PR Dominant Dominant £1349 
SMV+PR Dominant Dominant £3156 
SMV+SOF Dominant Dominant Dominant 
BOC+PEGIFN2b+RBV Dominant Dominant Dominant 
TVR+PEGIFN2a+RBV Dominant Dominant £1522 
PEG-IFN2a+RBV £7985 £10,397 £4731 
No treatment £7458 £8965 £4920 
Previously untreated genotype 4 HCV 
SOF+PR £3869 £6790 £1349 
SMV+PR £12,399 £23,136 £3156 
SMV+SOF Dominant Dominant Dominant 
PEG-IFN2a+RBV £12,715 £18,555 £4731 
No treatment £10,468 £13,734 £4920 
Previously treated genotype 1 or 4 HCV 
SOF+PR £5497 £3011 £11,001 
SMV+PR £9984 £10,494 £9102 
SMV+SOF Dominant Dominant SW quadrant1 
BOC+PEGIFN2b+RBV2 £3551 £5748 £1265 
TVR+PEGIFN2a+RBV2 £9144 £13,741 £4303 
PEG-IFN2a+RBV £12,491 £16,125 £6666 
No Treatment £13,527 £17,205 £7415 
Previously untreated genotype 3 HCV (LDV±SOF+RBV) 
SOF+PR £46,491 NA3 £46,491 
SOF+RBV £19,013 NA3 £19,013 
PR £26,491 £39,149 £17,622 
No treatment £11,235 £10,549 £12,335 
Previously treated genotype 3 HCV (LDV±SOF+RBV) 
SOF+RBV £6,210 NA3 £6,210 
No treatment £28,048 £33,631 £18,252 
Abbreviations: BOC, boceprevir; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; LDV, 
ledipasvir; PEG-IFN, peginterferon alfa; PR, peginterferon alfa + ribavirin; QALY; quality-adjusted life year; 
RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir.  
1 South West (SW) quadrant: ledipasvir±sofosbuvir results in cost savings but fewer QALYs.  
2
 TVR and BOC have a UK marketing authorisation for people with genotype 1 HCV only. Dominant ± 
comparator treatment gives fewer QALYs at greater cost than ledipasvir± sofosbuvir.  
3NA ± SOF+PR and SOF+RBV are not recommended in NICE guidance and hence excluded from the analysis. 
1RWH7KHFRPSDQ\¶V,&(5VIRUWKHVXEJURXSDQDO\VLVDUHIRUOHGLSDVYLU±sofosbuvir compared with the 
UHIHUHQFHFRPSDUDWRUIURPWKHFRPSDQ\¶VEDVH-case incremental analysis. If the company did an incremental 
analysis for its subgroup analysis, it may indicate alternative comparators. 
 
 
4.2.1 The (5*¶Vinterpretation of cost-effectiveness evidence 
 
The ERG¶VFULWLFDODSSUDLVDORI WKHFRPSDQ\¶VHFRQRPLFHYDOXDWLRQKLJKOLJKWHGDQXPEHURIFRQFHUQV7KHVH
include: (i) deviations from the NICE scope; (ii) the exclusion of relevant health effects relating to disease 
transmission and re-infection from the economic model; (iii) the use of naïve indirect comparisons to inform 
estimates of effectiveness which may be subject to bias and confounding; LY WKHXVHRI³EOHQGHG´ approach 
which take a weighted average of efficacy and treatment duration for LDV/SOF; (v) uncertainty regarding the 
HRQoL benefits of LDV/SOF whilst receiving treatment, and; (vi) discordance between some of the transition 
SUREDELOLWLHVDVVXPHGZLWKLQWKHFRPSDQ\¶VPRGHODQGWKRVHXVHGZLWKLQSUHYLRXVPRGHOVWRLQIRUPDSSUDLVDOV
of other antiviral therapies for the treatment of HCV.  
 
7KHFRPSDQ\¶V ³EOHQGHG´DSSURDFK used a weighted average of SVR rates and treatment durations for different 
options given over different treatment durations based on the expected proportion of patients who would receive 
each regimen. Consequently, the mean treatment duration, SVR rates, costs, treatment-specific HRQoL 
decrement avoided and ultimately, the cost-effectiveness of LDV/SOF, were dependent upon the proportion of 
SDWLHQWVLQHDFKSDUWRIWKH³EOHQG´The ERG considered that the blended analyses presented by the company 
are of limited value for decision-making as these may result in the simultaneous recommendation of some 
options which are known to be efficient and other options which are known to be inefficient. The ERG 
performed ³XQEOHQGHG´DQDO\VHVXVLQJWKHFRPSDQ\¶VPRGHOEDVHGRQ EMA recommended treatment durations 
for LDV/SOF+/-RBV [5]; this analysis formed WKH(5*¶VSUHIHUUHGEDVHFDVH 
 
The ERG undertook the following additional analyses to address issues identified within the critique of the 
FRPSDQ\¶VKHDOWKHFRQRPLFDQDO\VLV:  
1. The development of an ERG-SUHIHUUHG EDVH FDVH XVLQJ ³XQEOHQGHG´ (0$-recommended treatment 
durations [5] for LDV/SOF(+/-RBV)  
2. The consideration of alternative EMA-recommended treatment durations for LDV/SOF [5] 
3. The use of alternative transition probabilities based on the previous sofosbuvir STA model [12] 
4. The use of on-treatment utility increment derived by Wright et al [13] 
5. The use of shorter time horizons (5-years and 10-years) to dampen WKH FRPSDQ\¶V assumptions that 
patients cannot be re-infected after achieving an SVR. 
 
The results presented in Table 2 were produced after the submission of the ERG report [3] as additional analyses 
were undertaken by the ERG (at the request of the NICE AC). The AC requested that the comparators that were 
not recommended by NICE or not included in current clinical practice in England were excluded from the 
incremental analysis. . 
The ERG-preferred base case analysis suggested the following results. Within the GT1/4 treatment-naïve 
subgroup, in the non-cirrhotic population, the ICER for 12-weeks LDV/SOF versus SMV+PEG-IFN2a+RBV 
(the next most effective non-dominated option) is estimated to be £22,676 per QALY gained; within the 
cirrhotic population, the ICER for 24-weeks LDV/SOF versus SOF+PEG-IFN2a+RBV (the next most effective 
non-dominated option) is estimated to be £45,323 per QALY gained. Within the GT1/4 treatment-experienced 
subgroup, in the non-cirrhotic population, the ICER for 12-weeks LDV/SOF versus no treatment (the next most 
effective non-dominated option) is estimated to be £16,566 per QALY gained; within the cirrhotic population, 
the ICER for 24-weeks LDV/SOF versus SOF+PEG-IFN2a+RBV (the next most effective non-dominated 
option) is £32,458 per QALY gained. Within the GT3 treatment-naïve subgroup, in the non-cirrhotic population, 
the ICER for 24-weeks LDV/SOF+RBV versus PEG-IFN2a+RBV (the next most effective non-dominated 
option) is estimated to be £88,853 per QALY gained; within the cirrhotic population, the ICER for 24-weeks 
LDV/SOF+RBV versus SOF+PEG-IFN2a+RBV (the next most effective non-dominated option) is estimated to 
be £46,149 per QALY gained. Within the GT3 treatment-experienced subgroup, in the non-cirrhotic population, 
the ICER for 24-weeks LDV/SOF+RBV versus no treatment (the next most effective non-dominated option) is 
estimated to be £33,576 per QALY gained; within the cirrhotic population, the ICER for LDV/SOF versus no 
treatment (the next most effective non-dominated option) is estimated to be £18,238 per QALY gained.  
 
Table 2: Central estimates of cost-effectiveness from the ERG base case analysis 
Genotype 1/4 treatment-naïve non-cirrhotic  
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 12 weeks  17.20  £42,160.45 0.39 £8,843.83 £22,676 
SOF+PEG-IFN2a+RBV* 17.04  £41,081.62 - - ext dom 
SMV+PEG-IFN2a+RBV 16.81  £33,316.62 0.85 £14,111.22 £16,601 
TVR+PEG-IFN2a+RBV* 16.69  £34,631.46 - - Dominated 
BOC+PEG-IFN2b+RBV* 16.41  £35,002.22 - - Dominated 
PEG-IFN2a+RBV 15.96  £19,205.40 0.89 £6175.99 £6,939 
No treatment 15.07  £13,029.41 - - - 
(ii) Genotype 1/4 treatment-naïve cirrhotic  
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 24 weeks  10.08  £101,051.95 0.83 £37,618.44 £45,323 
SOF+PEG-IFN2a+RBV  9.25  £63,433.51 2.71 £15,167.91 £5,597 
SMV+PEG-IFN2a+RBV  8.28  £59,097.68 - - ext dom 
BOC+PEG-IFN2b+RBV*  8.09  £64,985.45 - - Dominated 
TVR+PEG-IFN2a+RBV*  7.95  £61,326.36 - - ext dom 
PEG-IFN2a+RBV  6.54  £48,265.60 1.29 £7,012.58 £5,436 
No treatment  5.25  £41,253.02 - - - 
Genotype 1/4 treatment-experienced non-cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 12 weeks  16.11  £41,978.77 1.80 £29,819.05 £16,566 
SOF+PEG-IFN2a+RBV*  15.71  £42,386.90 - - Dominated 
SMV+PEG-IFN2a+RBV  15.67  £38,729.70 - - ext dom 
TVR+PEG-IFN2a+RBV*  15.62  £36,459.92 - - ext dom 
BOC+PEG-IFN2b+RBV*  15.48  £39,911.38 - - Dominated 
PEG-IFN2a+RBV  14.61  £18,984.11 - - ext dom 
No treatment  14.31  £12,159.72 - - - 
(vi) Genotype 1/4 treatment-experienced cirrhotic  
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 24 weeks  9.70  £99,222.17 1.11 £36,028.74 £32,458 
SOF+PEG-IFN2a+RBV  8.59  £63,193.43 3.4 £22,542.63 £6,630 
SMV+PEG-IFN2a+RBV  8.31  £62,045.65 - - ext dom 
TVR+PEG-IFN2a+RBV*  7.46  £63,324.53 - - Dominated 
BOC+PEG-IFN2b+RBV*  6.95  £68,413.45 - - Dominated 
PEG-IFN2a+RBV  5.74  £47,441.22 - - ext dom 
No treatment  5.19  £40,650.80 - - - 
(vii) Genotype 3 treatment-naïve non-cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF+RBV 24 weeks  17.24  £83,330.76 0.81 £71,970.90 £88,853 
PEG-IFN2a+RBV  16.43  £11,359.86 - - - 
No treatment  14.57  £14,928.01 - - Dominated 
(viii) Genotype 3 treatment-naïve cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF+RBV 24 weeks  10.23  £102,644.92 0.85 £39,226.39 £46,149 
SOF+RBV  9.87  £95,947.03 - - ext dom 
SOF+PEG-IFN2a+RBV  9.38  £63,418.53 4.13 £22,165.51 £2,363 
No treatment  5.25  £41,253.02 - - - 
(ix) Genotype 3 treatment-experienced IFN-ineligible non-cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF+RBV 24 weeks  15.97  £84,108.64 2.09 £70,172.93 £33,576 
No treatment  13.88  £13,935.71 - - - 
(x) Genotype 3 treatment-experienced IFN-ineligible cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF+RBV 24 weeks  8.76  £105,760.87 3.57 £65,110.07 £18,238 
SOF+RBV  8.01  £101,108.73 - - ext dom 
No treatment  5.19  £40,650.80 - - - 
Abbreviations: BOC, boceprevir; HCV, hepatitis C virus; Inc. ± incremental, ICER, incremental cost 
effectiveness ratio; QALY, quality-adjusted life year; LDV, ledipasvir; LY, life years; PEGIFN+RBV, 
peginterferon alfa + ribavirin; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir. Dominated ± treatment 
gives fewer QALYs at greater cost than comparator. Ext dom ± a combination of 2 of its comparators 
provides equal health at a reduced cost 
*not applicable for genotype 4 patients  
 
 
The use of alternative EMA-recommended treatment durations had a substantial impact upon the cost-
effectiveness of LDV/SOF (see Table 3). Assuming a duration of treatment of 8 weeks for LDV/SOF in the 
GT1/4 treatment-naïve non-cirrhotic subgroup, the ICER for LDV/SOF versus PEG-IFN2a+RBV (the next most 
effective non-dominated option) is reduced to £8,894 per QALY gained. Assuming a duration of treatment of 12 
weeks for LDV/SOF within the GT1/4 treatment-naïve cirrhotic population, the ICER for LDV/SOF versus no 
treatment (the next most effective non-dominated option) is reduced to £4,518 per QALY gained. In the 
treatment-experienced GT1/4 non-cirrhotic subgroup, using a duration of treatment 24 weeks for LDV/SOF, the 
ICER for LDV/SOF versus SMV+PEG-IFN2a+RBV is estimated to be £77,495 per QALY gained. 
 
Table 3: Central estimates of cost-effectiveness using alternative EMA-recommended LDV/SOF 
treatment durations 
(i) Genotype 1/4 treatment-naïve non-cirrhotic  
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 8 weeks 17.12  £29,522.69 1.16 £10,317.29 £8,894 
SOF+PEG-IFN2a+RBV 17.04  £41,081.62 - - dominated 
SMV+PEG-IFN2a+RBV 16.81  £33,316.62 - - dominated 
TVR+PEG-IFN2a+RBV 16.69  £34,631.46 - - dominated 
BOC+PEG-IFN2b+RBV 16.41  £35,002.22 - - dominated 
PEG-IFN2a+RBV 15.96  £19,205.40 0.89 £6,175.99 £6,939 
No treatment 15.07  £13,029.41 - - - 
(ii) Genotype 1/4 treatment-naïve cirrhotic  
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 12 weeks  9.94  £62,440.44 4.69 £21,187.42 £4,518 
SOF+PEG-IFN2a+RBV  9.25  £63,433.51 - - dominated 
SMV+PEG-IFN2a+RBV  8.28  £59,097.68 - - ext dom 
BOC+PEG-IFN2b+RBV  8.09  £64,985.45 - - dominated 
TVR+PEG-IFN2a+RBV  7.95  £61,326.36 - - ext dom 
PEG-IFN2a+RBV  6.54  £48,265.60 - - ext dom 
No treatment  5.25  £41,253.02 - - - 
(iii) Genotype 1/4 treatment-experienced non-cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 24 weeks  16.21  £80,577.05 0.54 41847.35 £77,495 
SOF+PEG-IFN2a+RBV*  15.71  £42,386.90 - - ext dom 
SMV+PEG-IFN2a+RBV  15.67  £38,729.70 0.05 £2,269.78 £45,396 
TVR+PEG-IFN2a+RBV*  15.62  £36,459.92 1.31 £24,300.20 £18,550 
BOC+PEG-IFN2b+RBV*  15.48  £39,911.38 - - dominated 
PEG-IFN2a+RBV  14.61  £18,984.11 - - ext dom 
No treatment  14.31  £12,159.72 - - - 
(iv) Genotype 3 treatment-naive non-cirrhotic 
Option QALYs Costs Inc. QALYs Inc. costs ICER 
LDV/SOF 12 weeks  17.24  £42,997.49 0.81 £31,637.63 £39,277 
PEG-IFN2a+RBV  16.43  £11,359.86 - - - 
No treatment  14.57  £14,928.01 - - dominated 
Abbreviations: BOC, boceprevir; HCV, hepatitis C virus; Inc. ± incremental, ICER, incremental cost 
effectiveness ratio; QALY, quality-adjusted life year; LDV, ledipasvir; LY, life years; PEGIFN+RBV, 
peginterferon alfa + ribavirin; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir. Dominated ± treatment 
gives fewer QALYs at greater cost than comparator. Ext dom ± a combination of 2 of its comparators provides 
equal health at a reduced cost 
*not applicable for genotype 4 patients  
 
7KH(5*¶VDGGLWLRQDODQDO\VHV VXUURXQGLQJ WKHFRPSDQ\¶V WUDQVLWLRQSUREDELOLWLHVDQG WKH+54R/ LQFUHPHQW
associated with achieving SVR also produced different ICERs, however the overall conclusions of the economic 
analysis remain unaffected.   
 
7KH(5*¶VDnalyses which use shorter time horizons resulted in an increase in the ICERs for LDV/SOF (all of 
which are higher than £75,000 per QALY gained) compared with those estimated in the ERG-preferred base 
case analyses. This is unsurprising since the benefits are curtailed to a short time horizon yet the costs of 
treatment are incurred upfront. 
 
5 Conclusions of the ERG report 
7KH(5*EDVHFDVHDQDO\VHVXVLQJDQ³XQEOHQGHG´DQDO\VLVVXJJHVWed that the ICERs for LDV/SOF (+RBV) 
are dependent on a) duration of treatment, b) whether the patients are previously treated and c) cirrhosis status. 
In particular, the treatment duration chosen (within the EMA recommended treatment durations [5]) for the 
corresponding patient group has a marked impact on the cost-effectiveness results. In general, the economic 
profile of LDV/SOF (+RBV) appears considerably more favourable for shorter treatment durations due to their 
lower cost.  
 
6 Key methodological issues identified by the ERG 
 
The ERG had several concerns regarding the data and assumptions incorporated with the company¶V FRVW-
effectiveness analyses and conducted exploratory analyses to quantify the impact of making alternative 
assumptions and using alternative parameter inputs. Issues which appeared to have the most impact on the ICER 
were: WKHXVHRI³EOHQGHG´ approach and the choice of treatment duration. 
 
7 NICE guidance 
 
7.1 Key issues considered by the Appraisal Committee 
The AC reviewed the available evidence on clinical effectiveness and cost-effectiveness of LDV/SOF, having 
considered evidence on the nature of HCV and the value placed on the benefits of LDV/SOF by people with the 
condition, those who represent them, and clinical experts. It also took into account the effective use of NHS 
resources. 
 
The AC noted that the clinical effectiveness evidence was associated with considerable uncertainty namely: (i) 
the clinical study designs (open-label, non-randomised evidence, with no head-to-head studies); (ii) the selection 
of SVR rates for comparators from single studies, and (iii) the use of an naive indirect comparison to estimate 
relative treatment effects. 
 
The AC discussed the treatment durations and clinical effectiveness for LDV/SOF in GT1, GT3 and GT4 
patients with and without cirrhosis. The AC was concerned that the company had selected SVR rates from 
single studies without justification, particularly because this breaks the randomisation and also because no 
uncertainty associated with them was included LQ WKH FRPSDQ\¶V estimates of cost-effectiveness. The AC 
FRQFOXGHG WKDW WKH FRPSDQ\¶V HYLGHQFH on the relative effectiveness of LDV/SOF (with or without RBV) in 
people with GT1, 3 or 4 HCV was not robust, and that these aspects should be taken into account in the 
decision-making. 
 
The AC QRWHGWKDWWKHFRPSDQ\¶VHFRQRPLFPRGHOVWUXFWXUH grouped mild and moderate chronic hepatitis C into 
a single health VWDWHDQG WKHUHIRUH WKHFRPSDQ\¶VPRGHOGLVWLQJXLVKHGRQO\ between people with and without 
cirrhosis. The clinical experts acknowledged that the model structure was consistent with how people are 
diagnosed in clinical practice.  
 
The AC noted that the FRPSDQ\¶VEDVH-case analysis presented ICERs for a combined group of people with and 
without cirrhosis using weighted-average approach (i.e. µEOHQGHG¶ DSSURDFK). The AC was aware that the 
presence of cirrhosis affects the recommended regimen for LDV/SOF DQGDSHUVRQ¶VOLNHOLKRRGRIDQ695ZLWK
comparator treatments, and therefore the cost-effectiveness of treatment with LDV/SOF. The AC concluded that 
it was appropriate to use the approach taken in the (5*¶V H[SORUDWRU\ DQDO\VHV LQ OLQH ZLWK WKH PDUNHWLQJ 
authorisation, which considered people with and without cirrhosis separately, and estimated the cost-
effectiveness for each recommended treatment duration of LDV/SOF. 
 
The AC published preliminary recommendations for consultation and discussed the consultation comments at 
subsequent AC meetings. The AC also discussed the additional evidence provided by the company in response 
to consultation, which included cost-effectiveness results for the 12 weeks treatment experienced GT1 or 4 with 
cirrhosis group deemed at low risk of clinical disease progression. This resulted in a change in the 
recommendations for this patient group after the first ACD. Two ACDs and a FAD were produced for this STA.  
 
7.2 Final guidance 
The final NICE guidance published in November 2015 stated that: Ledipasvir±sofosbuvir is recommended as an 
option for treating chronic hepatitis C in adults, as specified in Table 4. 
 
Table 4. Final NICE guidance on Ledipasvir±sofosbuvir for treating adults with chronic hepatitis C 
HCV genotype, 
liver 
disease stage 
Duration 
(weeks) 
Recommendation according to treatment history 
Untreated Treated 
Ledipasvir±sofosbuvir 
1, without cirrhosis 
8 Recommended Not the licensed regimen for this population 
12 Not recommended Recommended 
24 Not the licensed regimen for this population Not recommended 
1, with compensated 
Cirrhosis 
12 Recommended Recommended only if all 
the following criteria are 
met: 
x Child±Pugh class A 
x platelet count of 
75,000/mm3 or more 
x no features of portal 
hypertension 
x no history of an HCV 
associated decompensation 
episode 
x not previously treated with 
an NS5A inhibitor. 
24 Not recommended Not recommended 
4, without cirrhosis 
12 Not recommended Recommended 
24 Not the licensed regimen for this population Not recommended 
4, with compensated 
Cirrhosis 
12 Recommended Recommended only if all 
the following criteria are 
met: 
x Child±Pugh class A 
x platelet count of 
75,000/mm3 or more 
x no features of portal 
hypertension 
x no history of an HCV 
associated decompensation 
episode 
x not previously treated with 
an NS5A inhibitor. 
24 Not recommended Not recommended 
Ledipasvir±sofosbuvir plus ribavirin 
1 Not the licensed regimen for this population 
3 24 Not recommended 
4 Not the licensed regimen for this population 
Abbreviation: HCV, hepatitis C virus. Treated ± WKHSHUVRQ¶VKHSDWLWLV&KDVQRWDGHTXDWHO\UHVSRQGHGWR
interferon-based treatment. 
 
8. Conclusions 
This paper describes the STA on LDV/SOF for treating chronic hepatitis C. 7KH³EOHQGHGFRPSDULVRQV´in CS 
combined some options which were efficient and other options which were inefficient. The ERG performed 
³XQEOHQGHG´ DQDO\VHV XVLQJ WKH FRPSDQ\¶V PRGHO EDVHG RQ (0$ UHFRPPHQGHG WUHDWPHQW GXUDWLRQV IRU
LDV/SOF (+RBV). Cost-effectiveness of LDV/SOF (+RBV) depended on the duration of treatment, whether 
the patients are previously treated and their cirrhosis status. LDV/SOF was recommended by NICE as a possible 
treatment option for subgroups of GT1 and GT4 patients.  
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